Hemic Or Immune System (e.g., Hematopoietic System, Bone Marrow Cells, Etc.) Patents (Class 424/577)
-
Patent number: 6143292Abstract: A method of treating a human cancer patient having a solid tumor comprising malignant cells is disclosed, wherein the patient having undergone a cancer therapy regimen comprising allogeneic stem cell transplantation. The method comprises administering allogeneic lymphocytes to the patient and monitoring the patient for levels of malignant cells.Type: GrantFiled: November 21, 1997Date of Patent: November 7, 2000Assignees: Baxter International Inc., Hadasit Medical Research Services and Development Ltd.Inventor: Shimon Slavin
-
Patent number: 6143535Abstract: A method is presented to remove contaminating tumor cells from a cell population. The method includes labeling individual tumor cells in the population and then killing them with a high energy laser beam. The laser is focused so that it specifically kills the identified tumor cell, but not the remaining cells in the population.Type: GrantFiled: March 27, 1998Date of Patent: November 7, 2000Inventor: Bernhard O. Palsson
-
Patent number: 6060049Abstract: This invention provides a method for developing immune tolerance in xenogeneic organ graft recipients, in which lympho-hematopoietic cells from an intended organ graft recipient are differentiated within a xenogeneic surrogate, such as a fetal animal. After birth of the surrogate, the matured lympho-hematopoietic cells containing antigen specific regulatory cells, including suppressor cells, veto cells, select B cells, anti-idiotype antibodies, and other related factors responsible for antigen specific tolerance in a surrogate animal are reintroduced into the intended organ graft recipient, in conjunction with an organ transplant or a tissue transplant from the xenograft surrogate. The invention also provides an organ graft repopulated with cells from the intended organ graft recipient produced in a surrogate animal.Type: GrantFiled: June 6, 1995Date of Patent: May 9, 2000Assignee: Ximerex, Inc.Inventor: William E. Beschorner
-
Patent number: 6054142Abstract: A biocompatible cell device having an internal foam scaffold to provide a growth surface for encapsulated cells which produce a biologically active molecule.Type: GrantFiled: August 1, 1996Date of Patent: April 25, 2000Assignee: Cyto Therapeutics, Inc.Inventors: Rebecca Li, Tyrone F. Hazlett
-
Patent number: 6015554Abstract: The invention relates to methods of enriching for hematopoietic cell populations enriched in myeloid and/or lymphoid progenitor cells based on cell specific markers. The methods also provide an enriched population of prethymic lymphoid-committed progenitor population lacking long-term hematopoietic reconstitution potential. Compositions enriched for the cells and populations of cells obtained therefrom are also provided by the invention. Methods of use of the cells are also included. Methods of genetically modifying the cells are provided as are cells obtained thereby.Type: GrantFiled: June 7, 1995Date of Patent: January 18, 2000Assignee: SyStemix, Inc.Inventor: Anne H. M. Galy
-
Patent number: 6010696Abstract: Method and preparations for enhancing hematopoietic progenitor cell engraftment in an individual by administering (i) a culturally expanded mesenchymal stem cell preparation and (ii) hematopoietic progenitor cells. The mesenchymal stem cells are administered in an amount effective to promote engraftment of the hematopoietic progenitor cells.Type: GrantFiled: March 25, 1998Date of Patent: January 4, 2000Assignee: Osiris Therapeutics, Inc.Inventors: Arnold I. Caplan, Stephen E. Haynesworth, Stanton L. Gerson, Hillard M. Lazarus
-
Patent number: 5994617Abstract: A process for transplanting into an immunodeficient mouse, which is deficient in T-cells and B-cells, human cells to form a chimeric mouse is provided. The transplanted human cells proliferate and thereby permit in vivo study of the human cells. The human cells are isolated from a human tissue source. The process comprises:i) irradiating an immunodeficient mouse deficient in T-cells and B-cells with radiation to condition the mouse for transplant:ii) transplanting into the irradiated mouse, the isolated human cells; andiii) maintaining the mouse to proliferate the human cells in and permit the human cells to spread in the mouse,to provide thereby a chimeric mouse incorporating the human cells in appropriate murine tissue.Type: GrantFiled: October 17, 1994Date of Patent: November 30, 1999Assignee: HSC Research Development CorporationInventors: John E. Dick, Suzanne Kamel-Reid
-
Patent number: 5922847Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies.Type: GrantFiled: June 7, 1994Date of Patent: July 13, 1999Assignee: Amgen Inc.Inventors: Virginia C. Broudy, Nancy Lin
-
Method for increasing neutrophil populations using in vitro-derived human neutrophil precursor cells
Patent number: 5888499Abstract: A suspension comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% human myeloblasts and promyeclocytes, which have been derived from neutrophis progenitor cells obtained from peripheral blood, bone marrow or cord blood, and less than about 5% colony forming units (CFU) of at least about 50 cells is provided. An alternative suspension comprising human neutrophil precursor cells, wherein the cellular component is comprised of at least about 16% CD15+CD11b- cells and less than about 5% colony forming units (CFU) of at least about 50 cells also is provided, wherein at least about 60% of the CD15+CD11b- cells are myeloblasts and promyelocytes. The suspensions of the invention are useful in methods for increasing neutrophil populations in a patient having a reduced populations of neutrophils.Type: GrantFiled: June 7, 1995Date of Patent: March 30, 1999Assignee: Nexell Therapeutics Inc.Inventors: James G. Bender, Phillip B. Maples, Stephen Smith, Kristen L. Unverzagt, Dennis E. Van Epps -
Patent number: 5874266Abstract: A method is presented to remove contaminating tumor cells from a cell population. The method includes labeling individual tumor cells in the population and then killing them with a high energy laser beam. The laser is focused so that it specifically kills the identified tumor cell, but not the remaining cells in the population.Type: GrantFiled: March 27, 1997Date of Patent: February 23, 1999Inventor: Bernhard O. Palsson
-
Patent number: 5851829Abstract: The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably a protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.Type: GrantFiled: March 30, 1995Date of Patent: December 22, 1998Assignee: Dana-Farber Cancer InstituteInventors: Wayne A. Marasco, William A. Haseltine
-
Patent number: 5820856Abstract: This invention provides a method of using modified human cytotoxic TALL-104 cell line, which is characterized by activity against tumor cells. More particularly, the method comprises treating bone marrow cells of an immunosuppressed mammalian patient with the modified TALL-104 cell line and reinjecting the treated bone marrow into the patient, as a treatment of hematological malignancies. Also provided are effective and safe methods of use of the modified cells in the manufacture of a veterinary composition for adoptive therapy of canine lymphoma and feline leukemias.Type: GrantFiled: December 8, 1995Date of Patent: October 13, 1998Assignee: The Wistar Institute of Anatomy and BiologyInventors: Daniela Santoli, Giovanni Rovera, Alessandra Cesano
-
Patent number: 5820872Abstract: Methods and pharmaceutical compositions for improving the effectiveness of radiation therapy for treating a subject having an internal solid tumor malignancy are disclosed. The methods include irradiating the tumor to release tumor-derived antigens in vivo, preparing a cellular vaccine including the isolated antigens admixed with a preparation of altered antigen presenting cells and administering the cellular vaccine to the subject. In the preferred embodiments, the antigen presenting cells are leukocytes that have been photochemically altered by subjecting the cells to photopheresis.Type: GrantFiled: July 30, 1993Date of Patent: October 13, 1998Assignee: Yale UniversityInventors: Richard L. Edelson, Francis P. Gasparro
-
Patent number: 5817773Abstract: Fibroblast growth factors are used in vivo, in situ and in vitro to stimulate stem cells, hemopoiesis, the immune system, transplant donor cells, culture and/or engraftment, wherein the use of fibroblast growth factors is disclosed for the stimulation of stem cells or hemopoietic cells, supporting cells and their progeny, in vitro, in situ and in vivo, as well as corresponding engrafting sites in vivo.Type: GrantFiled: February 23, 1996Date of Patent: October 6, 1998Assignees: New York University, Sloan-Kettering Institute for Cancer ResearchInventors: Elaine Lynette Wilson, Janice Gabrilove
-
Patent number: 5800539Abstract: The present invention provides a method of transplanting hematopoietic system reconstituting cells from a donor into an allogeneic recipient comprising administering to the recipient, prior to the administration of the hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated so as to render them incapable of proliferating and causing a lethal graft versus host disease effect, but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; and administering to the recipient an effective amount of hematopoietic system reconstituting cells.Type: GrantFiled: November 8, 1995Date of Patent: September 1, 1998Assignee: Emory UniversityInventor: Edmund K. Waller
-
Patent number: 5698767Abstract: Laboratory non-human animals in which the immune system of a donor is induced in and thrives in vivo and expresses the immune response of the donor animal in a recipient non-human animal of a different species than the donor, and wherein malignant immune system cells of the donor can be induced in the recipient non-human animal by injection of non-malignant donor into the recipient are disclosed.Type: GrantFiled: October 16, 1995Date of Patent: December 16, 1997Assignee: Lidak PharmaceuticalsInventors: Darcy B. Wilson, Donald E. Mosier
-
Patent number: 5652373Abstract: Non-human chimeric mammals are created from a mammal having hematopoietic cells replaced with hematopoietic cells from a hematopoietic deficient mammal donor, and optionally in which xenogeneic cells and/or tissue are engrafted. The xenogeneic, preferably human, cells or tissue may be hematopoietic cells, in which case the chimeric mammal can produce xenogeneic B and/or T cells, and can be used as a source of mammalian, preferably human, monoclonal antibodies and/or T cells. Alternatively, the xenogeneic cells or tissue may be non-hematopoietic, such as normal or pathological cells or tissue, which can form a stable transplant in the chimeric mammal and thus can be used as an animal model of various pathologies or to test therapeutic or diagnostic agents or modalities.Type: GrantFiled: May 17, 1993Date of Patent: July 29, 1997Assignee: Yeda Research and Development Co. Ltd.Inventor: Yair Reisner
-
Patent number: 5639939Abstract: Xenogeneic tissue is introduced into an immunocompromised host for interacting with agents and using such interaction for evaluating efficacy of drugs and vaccines, producing xenogeneic monoclonal antibodies, evaluating the effect of the various agents on specific tissues and the like. Particularly, drugs can be evaluated for their efficacy against a wide variety of pathogens which infect xenogeneic tissue, agents can be evaluated for their effect on the xenogeneic immune system and monoclonal antibodies to a predetermined epitope may be produced.Type: GrantFiled: March 1, 1994Date of Patent: June 17, 1997Assignee: The Board of Trustees for the Leland Stanford Junior UniversityInventor: Joseph M. McCune, III
-
Patent number: 5637323Abstract: This invention provides a method of isolating an increased number of hematopoietic stem cells from a subject comprising a) administering interleukin-7 to the subject in an amount that mobilizes the hematopoietic stem cells to the peripheral blood; and, b) isolating a population of leukocytes enriched for hematopoietic stem cells from the peripheral blood. Also provided is a method of transplanting an increased number of hematopoietic stem cells from a donor to a recipient to enhance repopulation of the recipient's hematopoietic and immune cells comprising a) administering interleukin-7 to the donor in an amount that mobilizes the hematopoietic stem cells to the peripheral blood; b) isolating a population of leukocytes enriched for hematopoietic stem cells from the donor's peripheral blood; and, c) transplanting the isolated population of leukocytes enriched for hematopoietic stem cells to the recipient, thereby enhancing the repopulation of the recipient's hematopoietic and immune cells.Type: GrantFiled: November 16, 1994Date of Patent: June 10, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Robert H. Wiltrout, Francis Ruscetti, Krzysztof Grzegorzewski, Jonathan Keller, Kristin L. Komschlies-McConville
-
Patent number: 5633426Abstract: Chimeric immunocompromised hosts are provided, comprising human bone marrow of at least 4 weeks from the time of implantation. The bone marrow is found to assume the normal population of bone marrow except for erythrocytes. The bone marrow may be used to study the effect of various agents on the proliferation and differentiation of hematopoietic cells.Type: GrantFiled: February 10, 1994Date of Patent: May 27, 1997Assignee: Systemix, Inc.Inventors: Reiko Namikawa, Seishi Kyoizumi, Joseph M. McCune, Hideto Kaneshima
-
Patent number: 5625127Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.Type: GrantFiled: May 4, 1995Date of Patent: April 29, 1997Assignee: SyStemix, Inc.Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph M. McCune
-
Patent number: 5614187Abstract: In general, the invention features, a method of inducing tolerance in a recipient mammal, e.g., a human, of a first species to a tissue obtained from a mammal, e.g., a swine, e.g., a miniature swine, of a second species, which tissue expresses an MHC antigen, including inserting DNA encoding an MHC antigen of the second species into a bone marrow hematopoietic stem cell from the recipient mammal, and allowing the MHC antigen encoding DNA to be expressed in the recipient.Type: GrantFiled: June 27, 1994Date of Patent: March 25, 1997Assignees: The General Hospital Corporation, The United States of America as represented by the Department of Health and Human ServicesInventor: David H. Sachs
-
Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
Patent number: 5612211Abstract: Fibroblast growth factors are used in vivo, in situ and in vitro to stimulate stem cells, hemopoiesis, the immune system, transplant donor cells, culture and/or engraftment, wherein the use of fibroblast growth factors is disclosed for the stimulation of stem cells or hemopoietic cells, supporting cells and their progeny, in vitro, in situ and in vivo, as well as corresponding engrafting sites in vivo.Type: GrantFiled: June 15, 1993Date of Patent: March 18, 1997Assignees: New York University, Sloan-Kettering Institute For Cancer ResearchInventors: Elaine L. Wilson, Janice Gabrilove -
Patent number: 5612018Abstract: A method is provided for screening compounds for the ability to supress thymocyte depletion in thymuses of HIV-infected individuals, particularly enhancing the CD4.sup.+ -expressing population as compared to an untreated individual. Particularly, drugs are provided which allow for this result, cyclosporine A being exemplary.Type: GrantFiled: January 18, 1994Date of Patent: March 18, 1997Assignee: Systemix, Inc.Inventors: Mark L. Bonyhadi, Hideto Kaneshima, Joseph M. McCune, Reiko Namikawa, Lishan Su
-
Patent number: 5585474Abstract: Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Gu erin and lipopolysaccharide.Type: GrantFiled: November 13, 1995Date of Patent: December 17, 1996Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kanso Iwaki, Tsunetaka Ohta, Masahi Kurimoto
-
Patent number: 5580769Abstract: A protein secreted by peripheral blood mononuclear specifically from CD8.sup.+ lymphocytes is purified and characterized here and designated CD8.sup.+ cell antiviral factor (CAF). The CAF is lipid free and has been found to inhibit the replication of retroviruses and in particular to inhibit the replication of HIV-1, HIV-2, and SIV. CAF can be used to inhibit viral RNA transcription which inhibits viral replication. Accordingly, CAF can be used to treat patients infected with retroviruses. The CAF can also generate antibodies which can be used to create assay devices for detecting CAF in a body fluid and on the surface of CD8.sup.+ cells to determine the condition of an HIV infected individual.Type: GrantFiled: September 16, 1994Date of Patent: December 3, 1996Assignee: The Regents of The University of CaliforniaInventors: Jay A. Levy, Carl E. Mackewicz
-
Patent number: 5565549Abstract: A protein secreted by peripheral blood mononuclear cells and specifically from CD8.sup.+ lyphocytes is purified and characterized here and designated CD8.sup.+ cell antiviral factor (CAF). The CAF is lipid free, has a molecular weight of less than 30,000 and has been found to inhibit the replication of retroviruses and in particular to inhibit the replication of HIV-1, HIV-2, and SIV. CAF can be used to inhibit viral RNA transcription which inhibits viral replication. Accordingly, CAF can be used to treat patients infected with retroviruses. The CAF can also generate antibodies which can be used to create assay reagents for detecting CAF in a body fluid and on the surface of CD8.sup.+ cells to determine the condition of an HIV infected individual.Type: GrantFiled: September 17, 1993Date of Patent: October 15, 1996Assignee: The Regents Of The University Of CaliforniaInventors: Jay A. Levy, Carl E. Mackewicz
-
Patent number: 5538713Abstract: Primordial tissue is introduced into immunodeficient hosts, where the primordial tissue develops and differentiates. The chimeric host allows for investigation of the processes and development of the xenogeneic tissue, testing for the effects of various agents on the growth and differentiation of the tissue, as well as identification of agents involved with the growth and differentiation.Type: GrantFiled: June 5, 1995Date of Patent: July 23, 1996Assignee: Systemix, Inc.Inventor: Bruno P eault
-
Patent number: 5510121Abstract: Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carders to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines.Type: GrantFiled: May 4, 1995Date of Patent: April 23, 1996Inventors: Woonza M. Rhee, Richard A. Berg
-
Patent number: 5498697Abstract: Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Guerin and lipopolysaccharide.Type: GrantFiled: September 27, 1993Date of Patent: March 12, 1996Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kanso Iwaki, Tsunetaka Ohta, Masashi Kurimoto
-
Patent number: 5476996Abstract: Laboratory non-human animals in which the immune system of a human donor is induced in and thrives in vivo and expresses the immune response of the human donor in a recipient non-human animal, and wherein malignant immune system cells of the human donor can be induced in the recipient non-human animal by injection of non-malignant donor cells into the recipient are disclosed.Type: GrantFiled: May 4, 1993Date of Patent: December 19, 1995Assignee: Lidak PharmaceuticalsInventors: Darcy B. Wilson, Donald E. Mosier
-
Patent number: 5476997Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.Type: GrantFiled: May 17, 1994Date of Patent: December 19, 1995Assignee: Systemix, Inc.Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph M. McCune
-
Patent number: 5462733Abstract: Methods and pharmaceutical compositions for modifying the immune response of a mammal are provided. The pharmaceutical compositions include a pharmaceutically acceptable carrier and a plurality of cells containing psoralen-DNA monoadducts and substantially no psoralen-DNA crosslinks. The preparation is formed by irradiating a suspension of cells with visible light radiation in the presence of psoralen.Type: GrantFiled: February 4, 1993Date of Patent: October 31, 1995Assignee: Yale UniversityInventors: Richard L. Edelson, Francis P. Gasparro
-
Patent number: 5342776Abstract: Avian hemopoietic progenitor cells of an earlier ontogenic stage than heretofore obtained are disclosed. The cells are produced by culturing suitable cells in a media containing avian embryo extract. Chicken hemopoietic progenitor cells and chicken embryo extract are preferred. Also disclosed are veterinary pharmaceutical formulations comprised of the earlier stage hemopoietic progenitor cells.Type: GrantFiled: September 4, 1992Date of Patent: August 30, 1994Inventors: Marie C. N. Bolnet, Francoise A. Dieterlen-Lievre
-
Patent number: 5294544Abstract: The invention comprises a factor having the following characteristics:a) It inhibits granulocyte-macrophage colony and cluster formation;b) It has a molecular weight of about 8 kDa as determined by SDS-PAGE;c) It has a weak anionic charge at pH 7.4 as shown by anion exchange chromatography;d) It has a flattened isoelectric titration curve as shown by anion exchange chromatography; andd) It is a protein.The invention also comprises methods of making and using the factor and compositions comprising the factor.Type: GrantFiled: May 22, 1992Date of Patent: March 15, 1994Assignee: Research Corporation Technologies, Inc.Inventors: Patrick S. Gentile, Charlie R. Mantel, Hal E. Broxmeyer
-
Patent number: 5226914Abstract: The present invention is directed to various processes and devices for utilizing isolated and culturally expanded marrow-derived mesenchymal cells (i.e. mesenchymal stem cells) for treating skeletal and other connective tissue disorders.Type: GrantFiled: November 16, 1990Date of Patent: July 13, 1993Inventors: Arnold I. Caplan, Stephen E. Haynesworth
-
Patent number: 5149544Abstract: The invention comprises a factor having the following characteristics:a) It inhibits granulocyte-macrophage colony and cluster formation;b) It has a molecular weight of about 8 kDa as determined by SDS-PAGE;c) It has a weak anionic charge at pH 7.4 as shown by anion exchange chromatography;d) It has a flattened isoelectric titration curve as shown by anion exchange chromatography; ande) It is a protein.The invention also comprises methods of making and using the factor and compositions comprising the factor.Type: GrantFiled: November 13, 1989Date of Patent: September 22, 1992Assignee: Research Corporation Technologies, Inc.Inventors: Patrick S. Gentile, Charlie R. Mantel, Hal E. Broxmeyer
-
Patent number: 5130144Abstract: Monoclonal antibodies that recognize a stage-specifc antigen on immature human marrow cells are provided. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marror transplantation. Cell suspensions containing human pluripotent lympho-hematopoietic stem cells are also provided, as well as theraputic methods employing the cell suspensions.Type: GrantFiled: March 22, 1991Date of Patent: July 14, 1992Assignee: The Johns Hopkins UniversityInventor: Curt I. Civin
-
Patent number: 5126148Abstract: Human hematopoietic cells produce metastasis-inhibitory factor (MIF). MIF exhibits a remarkable metastasis-inhibitory activity on viral diseases and immunopathies, as well as on malignant tumors. The MIF-producing human hematopoietic cells are easily proliferative by in vitro tissue culture and in vivo proliferation using a non-human warm-blooded animal. T cells exhibit a high MIF producibility. Mitogens augment the production of MIF when used as an MIF inducer.Type: GrantFiled: May 22, 1990Date of Patent: June 30, 1992Assignee: Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Masashi Kurimoto, Ryuichi Motoda, Kanso Iwaki
-
Patent number: 5108760Abstract: There is provided an improved process for enhanced LAK cell activation wherein the peripheral blood mononuclear cells are treated with an amino acid amide to yield depletion, prior to the lymphocytes being cultured at high density. Also provided are pharmaceutical compositions and methods of using them in combination with IL-2 to treat cancer in a mammal.Type: GrantFiled: July 21, 1989Date of Patent: April 28, 1992Assignee: Terumo CorporationInventors: Joseph D. Irr, Kam Leung
-
Patent number: 5087570Abstract: Highly concentrated hematopoietic stem cell compositions are provided which are substantially free of differentiated or dedicated hematopoietic cells. The cells are obtained by subtraction of cells having particular markers and selection of cells having particular markers. The resulting composition may be used to provide for individual or groups of hematopoietic lineages, to reconstitute stem cells of the host, and to identify an assay for a wide variety of hematopoietic growth factors.Type: GrantFiled: May 10, 1988Date of Patent: February 11, 1992Inventors: Irving L. Weissman, Gerald J. Spangrude, Christa Muller-Sieburg, Shelly Heimfeld
-
Patent number: 5081030Abstract: The present invention comprises a process for release from the cell-receptor complex of positively selected cells in viable, functional condition, where a ligand involved in the particular receptor-ligand interaction utilized for the affinity purification is selectively attacked by one or more degradative enzymes specific for that ligand. A resulting cell suspension can be obtained substantially free of receptor material.This invention, in one embodiment, contemplates a method for positive stem cell selection, utilizing anti-MY10 and immunomagnetic microspheres to isolate CD34-positive marrow cells and employing an enzyme to release micropheres from the isolated CD34-positive cells. Reproducible enzymatic cleaving of immunomagnetic microspheres from MY10-positive cells can be achieved by brief treatment of the preparation with papain or chymopapain. The isolated CD34-positive cells are particularly desirable for bone marrow transplantation.Type: GrantFiled: April 25, 1989Date of Patent: January 14, 1992Assignee: The Johns Hopkins UniversityInventor: Curt I. Civin